Skip to content
clinicaltrialshub.com
Clinical Trials Hub

Clinical trials, drug development and research news

Clinical Trials Hub: clinical trial and medical research news

The East Tower of Rush University Medical Center in Chicago, where the expanded access programme's lead investigator is based.
Rare Diseases

Spinal injection cut death risk by 55% in severe Niemann-Pick C

The FDA approved Lembaz (adrabetadex) on 17 November 2026 for infantile-onset Niemann-Pick C, after 36 treated patients had a 55% lower risk of death than matched untreated controls. A twice-monthly injection into the spinal fluid cut the risk of death by 55% in people with the severe, early form of Niemann-Pick disease type C (NPC), according to the analysis that led the US Food and Drug Administration to approve Lembaz (adrabetadex) on…

· 17 November 2026

The Briefing

Trial results that matter, every Friday.

One email. The week's readouts, approvals and research, explained without hype.

Latest

Oncology

More →

Rare Diseases

More →

Cardiology

More →

Neurology

More →

Drug Approvals

More →

Industry & Regulation

More →